Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Kobayashi Pharm. to Create 3 Subsidiaries in Southeast Asia
November 8, 2011
- Takeda Establishes New Positions in R&D, Global Sales
November 7, 2011
- Takeda Reinstates Request for Probe into Transfer Pricing Taxation
November 7, 2011
- Takeda: Sales, Profits Down due to Strong Yen, Double-digit Decreases in Sales of Actos in Apr-Sep
November 7, 2011
- Suzuken Reports Largest Interim Operating Loss From Drug Wholesale Business
November 7, 2011
- Operating Profits Down 70% in Wholesale Business: Alfresa HD
November 7, 2011
- 8 of 10 Leading Drug Makers Report Declines in 1st-Half Sales
November 7, 2011
- Takeda President Hasegawa Plans to Complete Integration with Nycomed in 3 Years
November 7, 2011
- Ono: Glactiv, Emend Drive Growth in 1st-Half Sales
November 7, 2011
- Astellas President Hatanaka Says Company Can Continue on Growth Path Through 2014
November 7, 2011
- Takara Bio: Research Reagents Drive Growth in Sales, Profits
November 7, 2011
- Kissei: Pharm. Sales Down 0.5%, Profits Up
November 7, 2011
- ASKA: Sales Down 8.4% Due to Rebound from a Spike at Last Fiscal Year End
November 7, 2011
- Breast Cancer Project Selected for Health Science Research Grant: 3-D Matrix
November 7, 2011
- Pharmacies Satisfied, Wholesalers Dissatisfied with Price Negotiations: Yano Research Survey
November 7, 2011
- CMIC: Sales, Profits Up Driven by CRO Business
November 7, 2011
- Kawasumi Lab.: Declines in Sales, Profits
November 7, 2011
- Sales of Actos Down 22% in 1st Half Due to Bladder Cancer Concerns, Generic Competition: Takeda
November 5, 2011
- Qol Decides to Discontinue “Dispensing Points” in March 2012
November 4, 2011
- Ono President Says Glactiv to “Still Show Advantage of Early Release”
November 4, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…